Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
obligations may continue. See	

OMB APPI	ROVAL				
OMB Number:	3235-0287				
Estimated average b	urden				
hours per response:	0.5				

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* VALE WYLIE W					2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [NBIX									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
VALE	WYLIE	<u>/V</u>			Ιī									X	Directo	r		10% Ov	vner
(Last)	(E	irst)	(Middle)		-										Officer below)	(give title		Other (s	specify
THE SALK INSTITUTE 10010 N.TORREY PINES ROAD					3. Date of Earliest Transaction (Month/Day/Year) 05/25/2011									•			ŕ		
				4.1	If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable					
(Street)														Line)	Form fi	led hy One	Reno	orting Perso	n
LA JOLI	LA C.	A	92037											21	Form f	led by More		One Repo	
(City)	(S	tate)	(Zip)		-										Person				
		Tab	le I - Nor	n-Deriv	vativ	e Se	curities	s Ac	quired	, Dis	posed c	of, or Be	nefic	ially	Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				ear) i	2A. Deemed Execution Date, if any (Month/Day/Year		, Transaction Code (Instr. 5		Disposed	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			5. Amour Securitie Beneficia Owned F	s ally ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
										v	Amount	mount (A) or (D)		ce	Transact	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)
		7	Fable II -								osed of, converti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date I Expirati (Month/I	n Dat		7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amor or Numl of Share	ber					
Stock Option ⁽¹⁾	\$7.05	05/25/2011			A		15,000		06/25/2	011	05/25/2018	Common Stock	15,0	000	\$0	15,000)	D	

Explanation of Responses:

1. Represents option of which 1/12th of the shares underlying the option becomes vested and exercisable on June 25, 2011, an additional 1/12th of the shares underlying the option becomes vested and exercisable each month thereafter.

Remarks:

Margaret E. Valeur-Jensen, By

05/25/2011

Power of Attorney ** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.